Medtronic (NYSE:MDT) said today that it’s starting a large study on the effect of pulse oximetry and capnography in opioid-induced respiratory depression, using its Capnostream device.
The 1,650-patient Prodigy study aims to create a tool to score the risk of OIRD in patients being treated with opioids for pain, using Capnostream’s continuous pulse oximetry and capnography monitoring over 48 hours. The study is slated for a final data collection for the primary outcome in February 2018 and an estimated completion date a month later, according to ClinicalTrials.gov.
Get the full story at our sister site, Drug Delivery Business News.